Every Form 4 that Elanco Animal Health (ELAN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELAN filings page.
Elanco Animal Health officer Ellen de Brabander reported equity compensation activity in the company’s common stock. On April 1, 2026, she received a grant of 40,985 shares, recorded at no purchase price. On the same date, 20,288 shares were disposed of at $23.12 per share to satisfy tax obligations, a tax-withholding transaction rather than an open-market sale. Following these entries, she directly holds 280,821 shares of Elanco common stock.
Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director K. Anand received an automatic grant of 600.7104 Deferred Stock Units as part of her director compensation. These units reflect cash retainer fees she chose to defer under the Company’s Directors' Deferral Plan, using a grant-date Elanco common stock price of $23.93.
Each Deferred Stock Unit is economically equivalent to one share of Elanco common stock and will be settled in stock when she separates from the Board. Following this award, she holds a total of 9,495.4518 Deferred Stock Units directly.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health reported that President and CEO Jeffrey N. Simmons received a grant of 117.887 deferred stock units on 2026-03-20. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent. Following this grant, Simmons directly holds a total of 23,795.2703 deferred stock units, which will settle in cash or shares after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health executive Rajeev A. Modi received a grant of 61.5901 deferred stock units tied to common stock. These units are part of an Executive Deferral and Stock Match Plan and will settle in cash or shares after employment ends or in a specified future year. Following this award, Modi holds 9,072.9178 deferred stock units.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.216 deferred stock units, each linked to one share of Elanco common stock or its cash equivalent. Following this grant, his reported deferred stock unit balance is 48.7929 units. These units will settle in cash or stock after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan, so this filing reflects compensation rather than an open‑market trade.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health executive Rajeev A. Modi received a grant of 1,360.2363 deferred stock units on Company common stock as compensation. The grant was valued at $23.36 per unit and increased his directly held deferred stock units to 9,011.3277.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan, making this a routine, non‑market award rather than an open‑market purchase.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc President and CEO Jeffrey N. Simmons received a grant of 4,497.6194 deferred stock units linked to the company’s common stock. Each unit represents the right to receive one share of common stock or the cash equivalent in the future, typically after employment ends or in a specified year. Following this award, his reported deferred stock unit balance is 23,677.3833 units, reflecting compensation rather than an open-market stock purchase or sale.
Elanco Animal Health executive vice president and CFO Robert M. VanHimbergen reported a compensation-related grant of deferred stock units. He acquired 9.485 deferred stock units tied to Company common stock, bringing his direct holding in this award type to 40.5769 units. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent, settling in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
Correia de Simas Jose Manuel reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health officer Correia de Simas Jose Manuel received a grant of 17,637.8425 deferred stock units on Company common stock at a reference value of $23.36 per unit. Following this award, he holds 22,280.4709 deferred stock units. These units will be settled in cash or shares after employment ends or in a designated future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc officer Rajeev A. Modi reported a tax-related share disposition. On 2026-03-03, he disposed of 4,392 shares of common stock through a tax-withholding disposition at $24.88 per share, leaving 155,901 shares held with direct ownership after the transaction.
Elanco Animal Health Inc general counsel and corporate secretary Shiv O'Neill reported a Form 4 transaction involving company common stock. On March 3, 2026, O'Neill had 4,738 shares disposed of in a tax-withholding disposition at $24.88 per share, leaving 83,834 shares of directly owned common stock reported after the transaction. This disposition reflects shares withheld to cover tax obligations rather than an open-market sale.
Elanco Animal Health Inc President, CEO and Director Jeffrey N. Simmons reported a tax-withholding disposition of 37,898 shares of common stock on March 3, 2026. The disposition, coded as a payment of tax liability, was priced at $24.88 per share.
After this transaction, Simmons directly held 2,051,898 shares of Elanco common stock. A separate line shows an indirect holding of 167,000 shares held by a revocable trust, reported as indirect beneficial ownership.
Elanco Animal Health Inc officer Timothy J. Bettington reported a tax-withholding disposition of 4,695 shares of common stock on March 3, 2026. The shares were transferred at $24.88 per share to cover tax obligations, rather than sold in an open-market transaction. After this transaction, Bettington directly held 143,261 shares of Elanco common stock.
Elanco Animal Health officer Cabral Ramiro Martin reported a tax-withholding disposition of 6,492 shares of common stock at $24.88 per share on March 3, 2026. After this non-market transaction, he directly owned 283,874 common shares.
Elanco Animal Health Inc officer Jose Manuel Correia de Simas reported a tax-related share disposition. On March 3, 2026, he transferred 3,371 shares of common stock at $24.88 per share to cover tax withholding, and held 101,017 shares directly afterward.
Elanco Animal Health Inc executive Ellen de Brabander reported a tax-related stock transaction. On this Form 4, she disposed of 8,262 shares of Common Stock on March 3, 2026 through a tax-withholding disposition at a price of $24.88 per share, leaving her with 260,124 directly owned shares.
Elanco Animal Health Inc executive David S. Kinard reported a Form 4 transaction involving company common stock. On March 3, 2026, Kinard had a tax-related disposition of 3,433 shares of common stock at a reported price of $24.88 per share. This transaction is coded as a tax-withholding disposition, meaning shares were surrendered to cover tax obligations rather than being sold on the open market. After this transaction, Kinard directly held 214,264 shares of Elanco Animal Health Inc common stock.
Elanco Animal Health Inc executive Grace McArdle, EVP, Manufacturing and Quality, reported a tax-related share disposition. On March 3, 2026, she disposed of 4,322 shares of Elanco common stock at $24.88 per share in a transaction classified as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in an open-market trade. Following this transaction, she directly held 103,705 shares of Elanco common stock.
Elanco Animal Health Inc chief accounting officer James M. Meer reported a tax-related share disposition. On the reported date, he transferred 1,389 shares of Common Stock at $24.88 per share to cover tax withholding obligations, a non-open-market transaction. After this, he directly held 66,732 Common Stock shares.
Elanco Animal Health chief accounting officer James M. Meer reported equity compensation and related tax withholding transactions in company common stock. He received grants classified as restricted stock units covering 9,596 shares and 5,209 shares, both at a stated price of $0.00 per share. A separate transaction disposed of 4,787 shares at $26.40 per share to satisfy tax liability by delivering shares. The restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health executive Rajeev A. Modi reported multiple equity awards and related tax withholding transactions. On March 1, 2026, he received 29,025 employee stock options and 2,532 deferred stock units at no cost. He was also granted 41,690 shares of common stock and an additional 14,205 restricted stock units, all as equity awards.
The stock options and restricted stock units each vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The deferred stock units vest on December 31, 2027 and settle in stock or cash upon termination of employment under the Executive Deferral and Stock Match Plan. To cover tax obligations, 19,375 common shares were disposed of at $26.40 per share through share delivery. Following these transactions, Modi directly owned 160,293 shares of Elanco common stock as of March 1, 2026.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported several equity-award transactions dated March 1, 2026. He acquired an employee stock option covering 243,809 shares and deferred stock units covering 6,593 shares. He also received grants of 397,041 and 119,319 shares of common stock. The restricted stock units and options vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The deferred stock units vest on December 31, 2027 and settle upon termination of employment or under the Executive Deferral and Stock Match Plan. A separate transaction disposed of 229,982 shares of common stock at $26.40 per share for tax-withholding purposes, leaving 1,970,477 shares of common stock held directly, plus 167,000 shares held indirectly by a revocable trust and shares previously acquired under the employee stock purchase plan.
Elanco Animal Health executive Jose Manuel Correia de Simas reported multiple equity compensation movements. He received an employee stock option grant for 23,220 shares at an exercise price of $0.0000 per share and 937 deferred stock units, both recorded as derivative awards.
He also acquired 21,507 and 11,364 shares of common stock as restricted stock unit grants, while 9,883 shares of common stock were disposed of at $26.40 per share to cover taxes, a tax-withholding disposition rather than an open-market sale. Footnotes state the option and stock unit grants vest in thirds on March 1, 2027, March 1, 2028, and March 1, 2029, with certain deferred units vesting on December 31, 2027.
Elanco Animal Health Inc officer Ramiro Martin Cabral reported several equity awards and related share movements. On March 1, 2026, he received an award of 42,570 stock options and separate grants of 60,053 and 20,834 shares of common stock at no cost.
The stock options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, subject to continued service. A separate disposition of 30,150 common shares at $26.40 per share was reported as a tax-withholding transaction, leaving 269,532 common shares held directly afterward.
Elanco Animal Health executive Grace McArdle reported new equity awards and related tax withholding transactions. On March 1, 2026 she received employee stock options for 29,025 shares and grants of 30,110 and 14,205 shares of common stock at no cost. A total of 12,337 shares of common stock at $26.40 per share were disposed of to cover tax liabilities. The options and restricted stock units vest in three equal installments on March 1, 2027, 2028, and 2029.
Elanco Animal Health executive David S. Kinard reported multiple equity awards and related tax withholding transactions. On March 1, 2026 he received 19,350 employee stock options and separate grants of 33,087 and 9,470 shares of common stock at no cost. A total of 15,377 common shares were disposed of at $26.40 per share to cover tax liabilities, leaving him with 217,697 common shares directly owned. The stock options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported equity awards that increase his stake in the company. He received an employee stock option grant for 48,375 shares at a price of $0.0000 per share and a separate grant of 23,675 shares of common stock, both classified as grant or award acquisitions.
According to the disclosure, the stock options vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The restricted stock units underlying the common stock grant vest on the same schedule. After the common stock grant, his directly held common stock position is 148,652 shares, which includes 744 shares acquired under the company’s employee stock purchase plan on January 31, 2026.
Elanco Animal Health general counsel and corporate secretary Shiv O'Neill reported equity compensation changes. On March 1, 2026, O'Neill received 29,993 stock options and 33,087 shares of common stock as grant or award acquisitions, all held directly.
The filing also shows a grant of an additional 14,679 common shares and a tax-withholding disposition of 13,111 common shares at $26.40 per share to cover tax obligations. The options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health officer Ellen de Brabander reported equity compensation changes. She received an employee stock option for 51,819 shares and grants of 67,564 and 25,360 shares of common stock, all at a price of $0.00 per share. A separate 46,278-share disposition at $26.40 per share covered tax obligations. The footnotes state that both the restricted stock units and stock options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health executive Timothy J. Bettington reported multiple equity transactions on March 1, 2026. He received an employee stock option grant for 19,350 options and several grants of common stock totaling 55,792 shares as awards. A separate transaction disposed of 18,098 common shares at $26.40 per share to cover tax withholding. The restricted stock units and stock options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health reported that officer Rajeev A. Modi acquired a grant of 56.6301 deferred stock units on Company stock, valued at $24.98 per unit. After this award, his direct holdings in these deferred stock units total 7,651.0914 units.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, these units are scheduled to settle in cash or shares after employment ends or in a specified future year.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported an acquisition of deferred stock units as part of his compensation. He received 110.8583 deferred stock units on Company common stock at a reference price of $24.98 per unit, described as a grant or award. After this award, his direct holdings of deferred stock units total 19,179.7639 units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and they settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 7.6217 deferred stock units at a reference price of $24.98 per unit. This award increases his directly held deferred stock units to 31.0919. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent, settling after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported a compensation-related grant of deferred stock units. On 02/06/2026 he acquired 7.5552 deferred stock units at $25.2 each, bringing his beneficially owned deferred stock units to 23.4702.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc. reported an insider equity award for its President, CEO and Director, Jeffrey N. Simmons, on February 6, 2026. He acquired 109.8905 deferred stock units at $25.2 per unit, bringing his directly held deferred stock units to 19,068.9056.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi reported a routine equity award. On February 6, 2026, he acquired 56.1357 deferred stock units at a reference price of $25.2 per unit. Following this transaction, he beneficially owned 7,594.4613 deferred stock units, held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health’s president and CEO Jeffrey N. Simmons reported an acquisition of derivative equity compensation. On January 23, 2026, he received 113.4934 deferred stock units at a reference price of $24.4 per unit, increasing his holdings to 18,959.0151 deferred stock units.
Each deferred stock unit gives the right to receive either one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi reported a routine equity compensation transaction. On 01/23/2026, he was awarded 57.9762 deferred stock units at a reference price of $24.4 per unit, increasing his beneficial holdings of these units to 7,538.3256, held directly.
The deferred stock units each represent the right to receive either one share of Elanco common stock or the cash equivalent. They will settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported an acquisition of derivative securities. On January 23, 2026, he acquired 7.8029 deferred stock units at a reference price of $24.4 per unit.
Following this transaction, he beneficially owned 15.915 deferred stock units directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi reported an award of deferred stock units. On 01/09/2026, he acquired 60.2735 deferred stock units at a value of $23.47 per unit, classified as a derivative security and held directly.
Following this transaction, Modi beneficially owned a total of 7,480.3494 deferred stock units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported a small compensation-related equity transaction. On 01/09/2026 he acquired 8.1121 deferred stock units at a reference price of $23.47 per unit, as disclosed on a Form 4.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and the units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan. After this transaction, he beneficially owns 8.1121 deferred stock units directly.
Elanco Animal Health Inc. CEO Jeffrey N. Simmons, who also serves as president and director, reported an acquisition of deferred stock units under a company plan. On January 9, 2026, he was credited with 117.9906 deferred stock units at a reference price of $23.47 per unit, bringing his total holdings to 18,845.5217 deferred stock units.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are designed to settle in cash or shares after employment ends or in a specified future year, in line with the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health director defers fees into stock units. Director Kapila K. Anand converted a portion of her cash director fees into deferred stock units under Elanco's Directors' Deferral Plan on December 31, 2025. She received 381.1312 Deferred Stock Units, each economically equivalent to one share of Elanco common stock, based on the closing share price of $22.63 on the grant date. Following this transaction, she held a total of 8,894.7414 deferred stock units, which will be settled in Elanco common stock when she separates from the Board of Directors.
Elanco Animal Health Inc. insider Jeffrey N. Simmons, the company’s President, CEO and Director, reported an acquisition of derivative securities in the form of deferred stock units on 12/26/2025. The filing shows he acquired 122.5327 deferred stock units tied to Elanco common stock at a derivative price of $22.6 per unit. Following this transaction, he beneficially owns 18,727.5311 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of Elanco common stock after termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive reports deferred stock unit grant. On 12/26/2025, an officer of Elanco Animal Health Inc. acquired 62.5938 deferred stock units under the company’s Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. Following this transaction, the reporting person beneficially owned 7,420.0759 deferred stock units, which will settle in cash or shares after employment ends or in a specified future year. The officer’s title is Executive Vice President U.S. Pet Health and Global Digital Transformation.
Elanco Animal Health Inc director reports charitable stock gift. Director R. David Hoover reported a transaction dated 12/19/2025 involving Elanco common stock. The filing shows that a revocable trust associated with him disposed of 60,000 shares as a gift to a charitable trust at a reported price of $0 per share.
After this gift, he is shown as beneficially owning 150,000 shares indirectly through a revocable trust, 106,773 shares directly, and 15,920 shares indirectly through the Suzanne A. Hoover Revocable Trust. This reflects a shift in how part of his holdings are allocated, with shares redirected to charitable purposes while maintaining substantial ownership interests.
Elanco Animal Health Inc. director Lawrence Kurzius reported an open-market purchase of company stock. On 12/12/2025, he bought 10,000 shares of Elanco common stock at a price of $21.3 per share. Following this transaction, his directly held beneficial ownership increased to 131,773 shares of Elanco common stock. The filing indicates that it was submitted for one reporting person, reflecting Kurzius’s role as a director of the company.
Elanco Animal Health Inc. officer Rajeev A. Modi reported acquiring additional deferred stock units tied to the company’s common stock. On 12/12/2025, he acquired 66.4453 deferred stock units at a price of $21.29 per unit, increasing his directly held deferred stock units to 7,357.4821.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, with settlement following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc. reported an insider equity transaction by its president, CEO and director, Jeffrey N. Simmons. On 12/12/2025 he acquired 130.0723 deferred stock units at $ 21.29 per unit, increasing his holdings to 18,604.9984 deferred stock units, held directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, reported an insider purchase of company stock. On December 11, 2025, he acquired 4,500 shares of Elanco common stock at a price of $21.33 per share.
After this transaction, Modi directly beneficially owns 123,082 Elanco shares. This total includes 1,579 shares acquired on January 31, 2025 and 205 shares acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.